307 related articles for article (PubMed ID: 26320246)
1. Single-Cell Analysis of B Cell/Antibody Cross-Reactivity Using a Novel Multicolor FluoroSpot Assay.
Hadjilaou A; Green AM; Coloma J; Harris E
J Immunol; 2015 Oct; 195(7):3490-6. PubMed ID: 26320246
[TBL] [Abstract][Full Text] [Related]
2. Multiplexed FluoroSpot for the Analysis of Dengue Virus- and Zika Virus-Specific and Cross-Reactive Memory B Cells.
Adam A; Woda M; Kounlavouth S; Rothman AL; Jarman RG; Cox JH; Ledgerwood JE; Gromowski GD; Currier JR; Friberg H; Mathew A
J Immunol; 2018 Dec; 201(12):3804-3814. PubMed ID: 30413671
[TBL] [Abstract][Full Text] [Related]
3. ELISPOT-Based "Multi-Color FluoroSpot" to Study Type-Specific and Cross-Reactive Responses in Memory B Cells after Dengue and Zika Virus Infections.
Andrade P; Coloma J; Harris E
Methods Mol Biol; 2018; 1808():151-163. PubMed ID: 29956181
[TBL] [Abstract][Full Text] [Related]
4. B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts.
Priyamvada L; Cho A; Onlamoon N; Zheng NY; Huang M; Kovalenkov Y; Chokephaibulkit K; Angkasekwinai N; Pattanapanyasat K; Ahmed R; Wilson PC; Wrammert J
J Virol; 2016 Jun; 90(12):5574-85. PubMed ID: 27030262
[TBL] [Abstract][Full Text] [Related]
5. Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones.
Smith SA; de Alwis AR; Kose N; Jadi RS; de Silva AM; Crowe JE
J Virol; 2014 Nov; 88(21):12233-41. PubMed ID: 25100837
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the Type-Specific and Cross-Reactive B-Cell Responses Elicited by a Live-Attenuated Tetravalent Dengue Vaccine.
Michlmayr D; Andrade P; Nascimento EJM; Parker A; Narvekar P; Dean HJ; Harris E
J Infect Dis; 2021 Feb; 223(2):247-257. PubMed ID: 32572472
[TBL] [Abstract][Full Text] [Related]
7. Primary and Secondary Dengue Virus Infections Elicit Similar Memory B-Cell Responses, but Breadth to Other Serotypes and Cross-Reactivity to Zika Virus Is Higher in Secondary Dengue.
Andrade P; Narvekar P; Montoya M; Michlmayr D; Balmaseda A; Coloma J; Harris E
J Infect Dis; 2020 Jul; 222(4):590-600. PubMed ID: 32193549
[TBL] [Abstract][Full Text] [Related]
8. Development and characterization of serotype-specific monoclonal antibodies against the dengue virus-4 (DENV-4) non-structural protein (NS1).
Gelanew T; Hunsperger E
Virol J; 2018 Feb; 15(1):30. PubMed ID: 29409531
[TBL] [Abstract][Full Text] [Related]
9. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.
Nivarthi UK; Kose N; Sapparapu G; Widman D; Gallichotte E; Pfaff JM; Doranz BJ; Weiskopf D; Sette A; Durbin AP; Whitehead SS; Baric R; Crowe JE; de Silva AM
J Virol; 2017 Mar; 91(5):. PubMed ID: 28031369
[TBL] [Abstract][Full Text] [Related]
10. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
[TBL] [Abstract][Full Text] [Related]
11. Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine.
Tsai WY; Chen HL; Tsai JJ; Dejnirattisai W; Jumnainsong A; Mongkolsapaya J; Screaton G; Crowe JE; Wang WK
J Virol; 2018 Dec; 92(23):. PubMed ID: 30185598
[TBL] [Abstract][Full Text] [Related]
12. B-cell responses during primary and secondary dengue virus infections in humans.
Mathew A; West K; Kalayanarooj S; Gibbons RV; Srikiatkhachorn A; Green S; Libraty D; Jaiswal S; Rothman AL
J Infect Dis; 2011 Nov; 204(10):1514-22. PubMed ID: 21930609
[TBL] [Abstract][Full Text] [Related]
13. Antibody Epitopes Identified in Critical Regions of Dengue Virus Nonstructural 1 Protein in Mouse Vaccination and Natural Human Infections.
Hertz T; Beatty PR; MacMillen Z; Killingbeck SS; Wang C; Harris E
J Immunol; 2017 May; 198(10):4025-4035. PubMed ID: 28381638
[TBL] [Abstract][Full Text] [Related]
14. Direct and indirect interactions in the recognition between a cross-neutralizing antibody and the four serotypes of dengue virus.
Lisova O; Belkadi L; Bedouelle H
J Mol Recognit; 2014 Apr; 27(4):205-14. PubMed ID: 24591178
[TBL] [Abstract][Full Text] [Related]
15. Universal Dengue Vaccine Elicits Neutralizing Antibodies against Strains from All Four Dengue Virus Serotypes.
Uno N; Ross TM
J Virol; 2021 Jan; 95(4):. PubMed ID: 33208445
[TBL] [Abstract][Full Text] [Related]
16. Serotype-specific anti-Dengue virus NS1 mouse antibodies cross-react with prM and are potentially involved in virus production.
Masrinoul P; Omokoko MD; Pambudi S; Ikuta K; Kurosu T
Viral Immunol; 2013 Aug; 26(4):250-8. PubMed ID: 23941673
[TBL] [Abstract][Full Text] [Related]
17. Development and characterization of mouse monoclonal antibodies against monomeric dengue virus non-structural glycoprotein 1 (NS1).
Gelanew T; Poole-Smith BK; Hunsperger E
J Virol Methods; 2015 Sep; 222():214-23. PubMed ID: 26070890
[TBL] [Abstract][Full Text] [Related]
18. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity.
Beltramello M; Williams KL; Simmons CP; Macagno A; Simonelli L; Quyen NT; Sukupolvi-Petty S; Navarro-Sanchez E; Young PR; de Silva AM; Rey FA; Varani L; Whitehead SS; Diamond MS; Harris E; Lanzavecchia A; Sallusto F
Cell Host Microbe; 2010 Sep; 8(3):271-83. PubMed ID: 20833378
[TBL] [Abstract][Full Text] [Related]
19. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
Khanam S; Pilankatta R; Khanna N; Swaminathan S
Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609
[TBL] [Abstract][Full Text] [Related]
20. High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection.
Tsai WY; Lai CY; Wu YC; Lin HE; Edwards C; Jumnainsong A; Kliks S; Halstead S; Mongkolsapaya J; Screaton GR; Wang WK
J Virol; 2013 Dec; 87(23):12562-75. PubMed ID: 24027331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
